Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SI | P14410 | 2/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30699124 | 0.85 | AR (0.40) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL27038551 | 0.85 | AR (0.40) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL20529669 | 0.79 | TDO2 (0.51) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL20529652 | 0.77 | SLC9A1 (0.58) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL31473638 | 0.77 | SLC9A1 (0.58) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL22153093 | 0.74 | FDPS (0.44) | RAB9AMAPTLMNA | |
| SCHEMBL22122575 | 0.74 | KMO (0.53) | KMO | |
| SCHEMBL31642496 | 0.74 | SLC9A1 (0.60) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL26449157 | 0.74 | AR (0.49) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL22122305 | 0.73 | GALR3 (0.42) | RAB9AALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | MGAM 3229/4885AMY1A 4033/4885GAA 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.